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Treatment of advanced colon cancer has improved 
over the past 15 years. Until the late 1990s, colorectal 
cancer was considered a chemoresistant disease, for 
which only ﬂ uorouracil could be oﬀ ered as a palliative 
treatment. However, many options are available today. 
The combination of chemotherapy and biological drugs—
including anti-EGFR or anti-VEGF antibodies—for ﬁ rst-line 
treatment, as well as the sequencing of diﬀ erent active 
drugs as disease progresses, can signiﬁ cantly improve 
outcomes.1 Median survival of patients included in clinical 
trials is often more than 2 years. Patients with initially 
unresectable metastatic disease limited to the liver can 
become resectable after treatment, with an opportunity 
for cure.2 Nevertheless, despite these advances, the 
optimal treatment for patients with advanced colorectal 
cancer in clinical practice is not yet deﬁ ned. Present 
subjects of debate include how to sequence diﬀ erent 
schedules of chemotherapy and biological treatment, 
duration of treatment, and how to personalise treatment. 
Predictive biomarkers can help doctors to select patients 
for individualised treatment. The addition of mutations in 
NRAS and KRAS exons 3 and 4 to the conventional exon 
2 KRAS mutations increases predictive value. Patients 
with all RAS wild-type tumours beneﬁ t greatly from 
treatment with the anti-EGFR antibodies cetuximab 
and panitumumab, whereas these drugs are harmful to 
patients with mutations in RAS.3,4 Moreover, no validated 
predictive biomarkers have been identiﬁ ed for anti-
angiogenic drugs. 
In this setting, Harpreet Wasan and colleagues5 
assessed two cetuximab regimens in combination with 
intermittent chemotherapy with FOLFOX (folinic acid and 
oxaliplatin followed by bolus and infused ﬂ uorouracil) as 
the backbone in a randomised phase 2 trial. Only patients 
with KRAS exon 2 wild-type were eligible. Retrospectively, 
they also analysed NRAS, BRAF, and other KRAS mutations. 
Their results from the previous COIN trial6 show that 
intermittent oxaliplatin-based combinations are eﬀ ective 
without causing any signiﬁ cant detrimental eﬀ ect on 
survival. However, despite this evidence, clinicians do not 
always consider fully stopping chemotherapy after 12 
weeks. Although oxaliplatin is halted when neurotoxicity 
occurs, or after 6 months of therapy, ﬂ uoropyrimidines 
and biological drugs are usually maintained until disease 
progression. In the COIN-B trial, the investigators 
challenged this strategy, assessing continuous and 
intermittent cetuximab when added to intermittent 
chemotherapy. In the intermittent cetuximab group, 
chemotherapy and cetuximab were only reintroduced on 
RECIST progression, which was assessed every 12 weeks 
after stopping treatment. In the maintenance cetuximab 
group, after 12 weeks of FOLFOX all patients continued 
with weekly cetuximab and only on RECIST progression 
was FOLFOX reintroduced.
The outcomes in each group in COIN-B should not be 
compared, since each group was powered as a separate 
phase 2 trial. The primary outcome was failure-free 
survival at 10 months among patients who completed 
12 weeks of treatment without progression, death, or 
leaving the trial for other reasons. The threshold that 
would lead to the regimens being tested in a conventional 
phase 3 design was a failure-free survival of 50% at 10 
months. This measure was met for both groups (50% 
for the intermittent cetuximab group and 52% for the 
continuous cetuximab group) in patients who had 
wild-type KRAS. These results were even better—as 
expected—for patients who also had wild-type NRAS, 
and BRAF. These data show the need for proper molecular 
classiﬁ cation of colorectal cancer, which would enable 
clinicians to select the most eﬀ ective treatment for 
patients. The ideal approach would be to select from all 
patients with wild-type genes those with tumours that 
are EGFR-driven and which would therefore beneﬁ t most 
from complete inhibition of EFGR. Some attempts at 
an eﬀ ective classiﬁ cation have already been made, but 
further validation in clinical trials is needed.7–9 
Another subject for further study is the dynamic process 
of clonal evolution in tumours. Under the selection 
pressure of continuous treatment, emerging RAS mutant 
clones could cause resistance to anti-EGFR antibodies.10 
Intermittent treatment might help to prevent the 
emergence of such clones. Liquid biopsies might identify 
the emergence of mutant clones and might also be useful 
for designing trials of biological treatments.11
We agree with the COIN-B investigators that their 
results cannot be translated into clinical practice without 
further validation in randomised phase 3 trials. However, 
COIN-B provides a clear hypothesis to test. Patients with 
EGFR-dependent tumours might need chemotherapy 
for only a short induction period followed by cetuximab 
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maintenance or reintroduction on progression. MRC 
FOCUS 4, a molecularly stratiﬁ ed, multisite randomised 
trial of patients with colorectal cancer—which has already 
started accrual in the UK—might help to deﬁ ne the best 
strategy to use.
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Introduction of adjuvant therapy with the monoclonal 
antibody trastuzumab has been the most signiﬁ cant 
advance in the management of women with early 
stage HER2-positive breast cancer, with improvement 
of disease-free and overall survival in these patients 
with a biologically aggressive subtype of the disease.1–4 
For patients with large operable or locally advanced 
breast cancer, induction (neoadjuvant) chemotherapy 
is a standard approach. The NOAH trial5 established for 
the ﬁ rst time that, in women with HER2-positive locally 
advanced or inﬂ ammatory breast cancer, addition of 
trastuzumab to neoadjuvant chemotherapy signiﬁ cantly 
increased the pathological complete response (pCR) 
compared with chemotherapy alone (35% vs 15%). In 
The Lancet Oncology, Luca Gianni and colleagues report 
the long-term results from NOAH.6 The updated results 
show that the beneﬁ t from addition of trastuzumab to 
chemotherapy in achievement of pathological complete 
response in the neoadjuvant setting translated into a 
signiﬁ cant eﬀ ect on the primary endpoint of event-free 
survival, with an unadjusted hazard ratio for event-free 
survival between the two randomised HER2-positive 
treatment groups of 0·64 (95% CI 0·44–0·93, p=0·016). 
Furthermore, the investigators report an improvement 
in overall survival.6 This study has helped to deﬁ ne the 
role of neoadjuvant trials as an appropriate setting for 
assessment of novel targeted therapies in subsets of 
early stage breast cancer.
The key to the success of this trial was appropriate 
patient selection for assessment of the targeted 
therapy—namely those with HER2-positive disease. 
Despite the small study size and subsequent crossover 
after the approval of adjuvant trastuzumab in 2005 
that potentially limited the ability of the NOAH trial to 
show a beneﬁ t on overall survival, a sensitivity analysis 
to account for the eﬀ ect of crossover still showed a 
signiﬁ cant reduction in risk of death with the addition 
of trastuzumab to chemotherapy. Patients allocated to 
neoadjuvant trastuzumab in this trial continued the drug 
in the adjuvant setting for 1 year, such that improvements 
in event-free survival and overall survival could have been 
aﬀ ected by trastuzumab given after surgery. However, the 
most relevant ﬁ nding from this updated analysis is that 
for those patients who achieved pathological complete 
response after neoadjuvant therapy, the HR for event-
free survival by treatment group was 0·29 (p=0·0135), 
which favours patients given trastuzumab, thus showing 
the signiﬁ cant eﬀ ect of neoadjuvant therapy with this 
